glutathione peroxidase inhibitor Frontiers AZD5904 | Glutathione Peroxidase Inhibitor

Ling Q, Herstine JA, Bradbury A et al (2023) AAV-based in vivo gene therapy for neurological disorders

450,451 In interim results from its phase II trial (NCT04693520), the drug lowered biomarker levels and showed the potential to slow the decline in memory and learning abilities in early AD patients carrying the APOE4 gene (either APOE4/4 or APOE3/4)

A 2021 study on vegan adults found high-dose oral methylcobalamin (1,000 mcg/day) effectively raised serum holotranscobalamin (the active B12 marker) to optimal levels within months, outperforming lower doses in maintaining steady stores

45 At the time of this publication, both subcutaneous liraglutide and semaglutide (2.4 mg weekly dose) are TGA approved for chronic weight management in Australia